Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,150 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Arteriosclerosis, Coronary Clear all
Completed Phase 2 Interventional Results available

Parasternal Nerve Block in Cardiac Patients

NCT01826851
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Postoperative
Interventions
Exparel, Placebo
Drug
Lead sponsor
Peter A Knight
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Apixaban in Recent Acute Coronary Syndrome

NCT00313300
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

NCT01324453
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Post Conditioning + Primary PCI, Standard Primary PCI
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

TAXUS PERSEUS Small Vessel

NCT00489541
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Bakersfield, California • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 16, 2026, 2:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Quantitative Cardiac Parametric Mapping

NCT02855554
View directory record Official record
Conditions
Cardiomyopathy, Myocarditis, Ischemic Heart Disease
Interventions
Cardiac Magnetic Resonance (CMR) imaging techniques
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 16, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictive Genetic Risk Assessment Trial

NCT00782366
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Not applicable Interventional Results available

EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

NCT01435031
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO)
Interventions
CTO Treatment Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

NCT01042769
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Aleglitazar, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
7,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
221
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 181 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 16, 2026, 2:29 AM EDT
Active, not recruiting No phase listed Observational

PRE-DETERMINE Cohort Study

NCT01114269
View directory record Official record
Conditions
Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
86
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

NCT02458690
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions
Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Not applicable Interventional Results available

Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

NCT01993017
View directory record Official record
Conditions
Acute Coronary Syndrome, Depressive Symptoms
Interventions
Cognitive Behavioral Therapy (CBT), Antidepressant Medication, Standard Care, Depressive symptom screener, No intervention
Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
1,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Bloomington, Minnesota • New York, New York • Henderson, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Not applicable Interventional

Cardiac Rehabilitation Program in Peripheral Arterial Disease

NCT03251391
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Cardiac Rehabilitation Program, Conventional Therapy
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Not applicable Interventional

Improving Outcomes and Quality of Life After CABG

NCT00256620
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery Patients
Interventions
Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
35 Years to 89 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

NCT01347710
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
73
States / cities
Mobile, Alabama • Scottsdale, Arizona • Beverly Hills, California + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 16, 2026, 2:29 AM EDT
Not listed No phase listed Observational

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

NCT01804543
View directory record Official record
Conditions
Angina, Heart Disease
Interventions
Ranolazine
Drug
Lead sponsor
Westside Medical Associates of Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle

NCT00361855
View directory record Official record
Conditions
Myocardial Infarction
Interventions
NX-CP105
Drug
Lead sponsor
Neuronyx
Industry
Eligibility
30 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2008 · Synced Oct 16, 2026, 2:29 AM EDT
Completed No phase listed Observational

Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease

NCT01018940
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Artery Disease
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

NCT00586820
View directory record Official record
Conditions
Myocardial Reperfusion Injury
Interventions
BQ-123, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 16, 2026, 2:29 AM EDT
Terminated Not applicable Interventional Results available

Women With Chest Pain and Normal Coronary Arteries Study

NCT00743197
View directory record Official record
Conditions
Chest Pain
Interventions
Aspirin, Lisinopril, Simvastatin, Lovaza, Therapeutic Lifestyle Changes
Drug · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 16, 2026, 2:29 AM EDT
Completed No phase listed Observational

DEFINing the PrEvalence and Characteristics of Coronary Artery Disease Among Patients With TYPE 2 Myocardial Infarction Using CT-FFR

NCT04864119
View directory record Official record
Conditions
Type 2 Myocardial Infarction
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 16, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

NCT01021865
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus Type 2
Interventions
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 16, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Genes That May Increase the Risk for Heart Disease in African Americans

NCT00344136
View directory record Official record
Conditions
Heart Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 95 Years
Enrollment
5,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 16, 2026, 2:29 AM EDT
Completed Not applicable Interventional Results available

Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol

NCT00853632
View directory record Official record
Conditions
Coronary Artery Disease, Mitral Valve Regurgitation, Mitral Valve Incompetence, Heart Failure
Interventions
CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
10
States / cities
Sacramento, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 16, 2026, 2:29 AM EDT
Withdrawn Not applicable Interventional

Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREAT MI Study

NCT03284281
View directory record Official record
Conditions
STEMI - ST Elevation Myocardial Infarction, Inflammation
Interventions
Tragus stimulator, Sham Tragus stimulator
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 16, 2026, 2:29 AM EDT